Mural Oncology PLC

News & Events zu Mural Oncology PLC (MURA)

$2.040

0.000 (0.00%)Zum Schluss

MURA-News

MURA-Events

12/5 09:10

XOMA Completes Acquisition of Entire Share Capital of Mural Oncology

XOMA Royalty (XOMA) completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology (MURA) pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland. Mural shareholders received $2.035 in cash per share. The Acquisition was approved by Mural shareholders at a special meeting of shareholders convened pursuant to section 450(1) of the Irish Companies Act 2014 and an extraordinary general meeting of shareholders held on October 24, 2025. The Irish High Court sanctioned the Scheme on December 3, 2025. On December 5, 2025, the Scheme and the Acquisition became effective upon delivery of the court order to the Irish Companies Registration Office. Prior to the opening of trading on December 5, 2025, all of Mural's shares will cease trading on Nasdaq, and Mural intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.

12/5 07:50

Mural Oncology Announces Scheme of Arrangement Effective

Mural Oncology (MURA) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 pursuant to which XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation (XOMA) will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025. Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon as practicable following the Effective Date, with DTC participant accounts expected to be credited and the distribution of cheques expected to be complete as soon as practicable. In accordance with the requirements of the Irish Takeover Rules, all consideration paid by Sub to Scheme Shareholders under the terms of the Scheme will be distributed by no later than 19 December 2025.

11/26 09:04

Mural Oncology Reveals Final Cash Payment Due Upon Acquisition Completion

Mural Oncology (MURA) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (XOMA), XRA 5 Corp. and Mural announced on August 20, the Additional Price Per Share has been finally determined in accordance with Clause 2.4 of the Transaction Agreement as $0.000. As a result, the total cash consideration payable to Mural shareholders on closing of the Acquisition will be $2.035 in cash per share. As previously announced on August 20, 2025, XOMA Royalty, Sub and Mural entered into the Transaction Agreement pursuant to which Sub, a wholly-owned subsidiary of XOMA Royalty, has agreed to acquire the entire issued and to be issued share capital of Mural pursuant to an Irish High Court sanctioned "scheme of arrangement" under Chapter 1 of Part 9 of the Irish Companies Act of 2014. The Acquisition is expected to close in early December 2025, subject to the satisfaction of the outstanding closing conditions and the sanction of the Scheme by the Irish High Court.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten